Search Result

Results for "

antinociceptive effect

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (3) Angiotensin Receptor (1) Antibiotic (1) Apoptosis (7) Bacterial (3) Calcium Channel (1) Cannabinoid Receptor (1) Carboxypeptidase (1) COX (3) Drug Derivative (1) Endogenous Metabolite (3) Environmental Pollutants (2) ERK (3) Fungal (3) GlyT (2) GPR35 (3) iGluR (1) Isotope-Labeled Compounds (1) nAChR (3) Opioid Receptor (11) P2X Receptor (6) PKA (5) Reactive Oxygen Species (ROS) (7) Reference Standards (10) ROCK (2) TRP Channel (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (2) Endocrinology (1) Infection (2) Inflammation/Immunology (22) Metabolic Disease (1) Neurological Disease (39)

By Targets:

Adenosine Receptor (3)

Angiotensin Receptor (1)

Antibiotic (1)

Apoptosis (7)

Bacterial (3)

Calcium Channel (1)

Cannabinoid Receptor (1)

Carboxypeptidase (1)

COX (3)

Drug Derivative (1)

Endogenous Metabolite (3)

Environmental Pollutants (2)

ERK (3)

Fungal (3)

GlyT (2)

GPR35 (3)

iGluR (1)

Isotope-Labeled Compounds (1)

nAChR (3)

Opioid Receptor (11)

P2X Receptor (6)

PKA (5)

Reactive Oxygen Species (ROS) (7)

Reference Standards (10)

ROCK (2)

TRP Channel (1)

By Research Areas:

Cancer (11)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (22)

Metabolic Disease (1)

Neurological Disease (39)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0764

Bucladesine sodium Maximum Cited Publications 41 Publications Verification Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-N0709

Coumarin 3 Publications Verification	Environmental Pollutants Bacterial Fungal	Infection Neurological Disease Inflammation/Immunology Cancer
Coumarin is a potent and orally active anti-inflammatory agent. Coumarin shows an antinociceptive effect. Coumarin shows antibacterial, antifungal and anticancer activity .

HY-108652

α,β-Methylene-ATP trisodium 1 Publications Verification	P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP trisodium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .

HY-Y0892

4-Hydroxybenzyl alcohol 1 Publications Verification	Apoptosis Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
4-Hydroxybenzyl alcohol is a phenolic compound widely distributed in various kinds of plants. Anti-inflammatory, anti-oxidant, anti-nociceptive activity. Neuroprotective effect. Inhibitor of tumor angiogenesis and growth .

HY-N3017

Artemitin 1 Publications Verification	Antibiotic	Neurological Disease Inflammation/Immunology
Artemitin is a flavonoid neuroanesthetic agent with moderate cytotoxicity. Artemitint has selective inhibitory activity against Meth-A sarcoma cells with an ED₅₀ of 5-10 μg/mL, and has no significant effect on LLC lung cancer cells. Artemitin exerts anticancer activity by affecting cell proliferation signaling pathways, and also has potential anti-inflammatory and neuroprotective effects. Artemitin exhibits a dose-dependent antinociceptive effect in the mouse hot plate test, with an ED₅₀ of 1.6 μg/kg, and has analgesic activity .

HY-B0764A

Bucladesine hemicalcium Maximum Cited Publications 41 Publications Verification Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium	PKA Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-W008613

Pamoic acid 5 Publications Verification Embonic acid	GPR35 ERK	Neurological Disease Inflammation/Immunology
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC₅₀ of 79 nM. Pamoic acid exhibits neuroprotective and anti-inflammatory properties .

HY-107944

Chlorphenesin carbamate Maolate; U 19646	Drug Derivative	Neurological Disease
Chlorphenesin carbamate is a centrally acting skeletal muscle relaxant, as well as a derivate of Chlorphenesin (HY-A0133). Chlorphenesin carbamate can be used for the research of pain and discomfort related to skeletal muscle trauma and inflammation . Chlorphenesin carbamate is a selective blocker of polysynaptic pathways at the spinal and supra-spinal levels . Antinociceptive effect .

HY-17391

Pamabrom	Adenosine Receptor	Endocrinology
Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K ⁺ channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea[1].

HY-N1478

Gardenoside 2 Publications Verification	P2X Receptor Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
Gardenoside is an orally active natural compound found in Gardenia fruits. Gardenoside reliefs chronic constriction injury (CCI)-induced neuropathic pain by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside reduces reactive oxygen species (ROS). Gardenoside can be used for anti-inflammatory, antinociceptive and hepatoprotective study .

HY-P1626

Acetyl tetrapeptide-15	Opioid Receptor	Neurological Disease
Acetyl tetrapeptide-15 is a synthetic peptide. Acetyl tetrapeptide-15 is derived from endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), a human μ-opioid agonist with selective anti-nociceptive effect. Acetyl tetrapeptide-15 reduces skin hyperreactivity producing inflammatory, chronic and neuropathic pain, by increasing the threshold of neuronal excitability in μ-opioid receptor via an endorphin-like pathway. Acetyl tetrapeptide-15 is used in the cosmetics for sensitive skin .

HY-W010907

Pamoic acid disodium 4 Publications Verification	GPR35 ERK	Neurological Disease
Pamoic acid disodium is a potent GPR35 agonist with an EC₅₀ value of 79 nM. Pamoic acid disodium induces GPR35 internalization and activates ERK1/2 with EC₅₀ values of 22 nM and 65 nM, respectively. Pamoic acid disodium potently recruits β-arrestin2 to GPR35 and has an antinociceptive effect .

HY-P1074

SNX-482 1 Publications Verification	Calcium Channel	Neurological Disease
SNX-482, a peptide, is a potent, high affinity, selective and voltage-dependent R-type Ca_V2.3 channel blocker with an IC₅₀ of 30 nM. SNX-482 has antinociceptive effect .

HY-108519

AS1892802	ROCK	Neurological Disease
AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-N6663

3-Carene	Environmental Pollutants COX	Inflammation/Immunology
3-Carene is a bicyclic monoterpene in essential oils extracted from pine trees. 3-Carene inhibits nociceptive stimulus-induced inflammatory infiltrates and COX-2 overexpression, and with antinociceptive effect. 3-Carene stimulates the activity and expression of alkaline phosphatase that is an early phase marker of osteoblastic differentiation .

HY-134440A

α,β-Methylene-ATP	P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .

HY-N0092R

Inosine (Standard)	Reference Standards Adenosine Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Inosine (Standard) is the analytical standard of Inosine. This product is intended for research and analytical applications. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors . In Vitro:Inosine dose-dependently stimulates cAMP production mediated through the A_2AR . Inosine dose-dependently induces hA_2AR-mediated ERK1/2 phosphorylation . Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes . In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice .

HY-B0764B

Bucladesine Dibutyryl cAMP; DBcAMP	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-147907

Adenosine receptor inhibitor 1	Adenosine Receptor	Neurological Disease Inflammation/Immunology Cancer
Adenosine receptor inhibitor 1 is a potent and selective adenosine receptor (AR) inhibitor with K_i values of >1000, 68.5, >1000, >1000 nM for A₁AR, A_2AAR, A_2BAR, A₃AR, respectively. Adenosine receptor inhibitor 1 shows antinociceptive activity, anti-inflammatory effect and peripheral analgesic effect. Adenosine receptor inhibitor 1 has the potential for the research of cancer or neurodegenerative diseases .

HY-111029A

ALX-1393 TFA	GlyT	Others
ALX-1393 TFA, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-101205

ICI-199441 hydrochloride	Opioid Receptor	Cardiovascular Disease Neurological Disease
ICI-199441 hydrochloride is a potent and selective κ-opioid receptor agonist with analgesic effects. ICI 199441 hydrochloride can improve heart resistance to ischemia/reperfusion .

HY-N0709R

Coumarin (Standard)	Reference Standards Bacterial Fungal	Infection Neurological Disease Inflammation/Immunology Cancer
Coumarin (Standard) is the analytical standard of Coumarin. This product is intended for research and analytical applications. Coumarin is a potent and orally active anti-inflammatory agent. Coumarin shows an antinociceptive effect. Coumarin shows antibacterial, antifungal and anticancer activity .

HY-136207

TC-2559 difumarate	nAChR	Neurological Disease
TC-2559 idifumarate is a CNS-selective, orally active α4β2 subtype of nicotinic acetylcholine receptor (nAChR) partial agonist (EC₅₀=0.18 μM). TC-2559 difumarate shows selectivity for α4β2 over α2β4, α4β4 and α3β4 receptors, with EC₅₀s in the range of 10-30 µM. Antinociceptive effect .

HY-B0764G

Bucladesine sodium Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-111029

ALX-1393	GlyT	Neurological Disease
ALX-1393, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model .

HY-P1044

Spinorphin LVV-hemorphin-4	Carboxypeptidase	Neurological Disease
Spinorphin is an inhibitor of enkephalin-degrading enzymes. Spinorphin inhibits aminopeptidase, dipeptidyl aminopeptidase III, angiotensin-converting enzyme and enkephalinase. Spinorphin possesses an antinociceptive effect .

HY-P1044A

Spinorphin TFA LVV-hemorphin-4 TFA	Angiotensin Receptor	Neurological Disease
Spinorphin TFA is an inhibitor of enkephalin-degrading enzymes. Spinorphin inhibits aminopeptidase, dipeptidyl aminopeptidase III, angiotensin-converting enzyme and enkephalinase. Spinorphin possesses an antinociceptive effect .

HY-B0764R

Bucladesine sodium (Standard) Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)	Reference Standards PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-Y0892R

4-Hydroxybenzyl alcohol (Standard)	Reference Standards Apoptosis Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
4-Hydroxybenzyl alcohol (Standard) is the analytical standard of 4-Hydroxybenzyl alcohol. This product is intended for research and analytical applications. 4-Hydroxybenzyl alcohol is a phenolic compound widely distributed in various kinds of plants. Anti-inflammatory, anti-oxidant, anti-nociceptive activity. Neuroprotective effect. Inhibitor of tumor angiogenesis and growth [4].

HY-P6053

KK-103	Opioid Receptor	Neurological Disease
KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .

HY-N0709S1

Coumarin-d6	Bacterial Fungal Isotope-Labeled Compounds	Cancer
Coumarin-d₆ is deuterated labeled Coumarin (HY-N0709). Coumarin is a potent and orally active anti-inflammatory agent. Coumarin shows an antinociceptive effect. Coumarin shows antibacterial, antifungal and anticancer activity .

HY-101317A

TAN-67 SB-205607	Opioid Receptor	Metabolic Disease
TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.

HY-134440

α,β-Methylene-ATP dilithium	P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP dilithium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP dilithium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP dilithium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP dilithium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .

HY-N1478R

Gardenoside (Standard)	Reference Standards P2X Receptor Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
Gardenoside is an orally active natural compound found in Gardenia fruits. Gardenoside reliefs chronic constriction injury (CCI)-induced neuropathic pain by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis. Gardenoside reduces reactive oxygen species (ROS). Gardenoside can be used for anti-inflammatory, antinociceptive and hepatoprotective study .

HY-176063

TRPV1 antagonist 11	TRP Channel Opioid Receptor	Neurological Disease
TRPV1 antagonist 11 (compound 2ac) is a potent TRPV1 antagonist with an IC₅₀ of 29.3 nM. TRPV1 antagonist 11 is a potent μ-opioid receptor (MOR) agonist with a K_i of 60.3 nM. TRPV1 antagonist 11, a pyrimidine piperazine, exhibits pain relieving effects by antagonizing TRPV1 and stimulating MOR. TRPV1 antagonist 11 shows a potent, dose-dependent anti-nociceptive effect in a Formalin-induced pain model in mice .

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

HY-136623

BW443C	Opioid Receptor	Neurological Disease
BW443C is a selective opioid receptor agonist. BW443C has antinociceptive effect .

HY-W008613R

Pamoic acid (Standard) Embonic acid (Standard)	Reference Standards GPR35 ERK	Neurological Disease Inflammation/Immunology
Pamoic acid (Standard) is the analytical standard of Pamoic acid. This product is intended for research and analytical applications. Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC₅₀ of 79 nM. Pamoic acid exhibits neuroprotective and anti-inflammatory properties .

HY-103341

UCM707	Cannabinoid Receptor	Neurological Disease
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide .

HY-19206

R-84760	Opioid Receptor	Neurological Disease
R-84760 is a selective κ-opioid receptor agonist. R-84760 has antinociceptive effect .

HY-W325509

AH 8532	Opioid Receptor	Neurological Disease
AH 8532, an opioid, possesses anti-nociceptive effect and inhibits writhing induced by phenylquinone, with a ED₅₀ of 16 mg/kg in mice orally .

HY-14316C

Tebanicline tosylate Ebanicline tosylate; ABT-594 tosylate	nAChR	Neurological Disease
Tebanicline tosylate, an analogue of epibatidine, is a neuronal nicotinic acetylcholine receptor agonist. Tebanicline tosylate exhibits potent antinociceptive effects and has a high affinity for the α4β2 neuronal nicotinic acetylcholine receptor subunit in the central nervous system.

HY-14316

Tebanicline Ebanicline; ABT-594	nAChR	Neurological Disease
Tebanicline, an analogue of epibatidine, is a neuronal nicotinic acetylcholine receptor agonist. Tebanicline exhibits potent antinociceptive effects and has a high affinity for the α4β2 neuronal nicotinic acetylcholine receptor subunit in the central nervous system.

HY-101205A

ICI-199441	Opioid Receptor	Cardiovascular Disease Neurological Disease
ICI-199441 is a potent and selective κ-opioid receptor agonist with analgesic effects. ICI 199441 can improve heart resistance to ischemia/reperfusion .

HY-107944R

Chlorphenesin carbamate (Standard) Maolate (Standard); U 19646 (Standard)	iGluR Reference Standards	Neurological Disease
Chlorphenesin carbamate (Standard) is the analytical standard of Chlorphenesin carbamate. This product is intended for research and analytical applications. Chlorphenesin carbamate is a centrally acting skeletal muscle relaxant. Chlorphenesin carbamate can be used for the research of pain and discomfort related to skeletal muscle trauma and inflammation . Chlorphenesin carbamate is a selective blocker of polysynaptic pathways at the spinal and supra-spinal levels . Antinociceptive effect .

HY-N6663R

3-Carene (Standard)	Reference Standards COX	Inflammation/Immunology
3-Carene (Standard) is the analytical standard of 3-Carene. This product is intended for research and analytical applications. 3-Carene is a bicyclic monoterpene in essential oils extracted from pine trees. 3-Carene inhibits nociceptive stimulus-induced inflammatory infiltrates and COX-2 overexpression, and with antinociceptive effect. 3-Carene stimulates the activity and expression of alkaline phosphatase that is an early phase marker of osteoblastic differentiation .

HY-105142

M-5011	COX	Inflammation/Immunology
M-5011 is a potent and orally active anti-inflammatory agent. M-5011 shows potent antinociceptive effects and inhibits kaolin (HY-W115786)-induced writhing. M-5011 decreases peritoneal 6-keto-PGF1 alpha levels with low ulcerogenic activities. M-5011 shows anti-inflammatory and anti-pyretic effects and analgesic effect .

HY-161539

KOR agonist 1	Opioid Receptor	Neurological Disease
KOR agonist 1 (Compound 7a) is a selective agonist for opioid receptor, with EC₅₀s of 3.4, 701.2 and 1649 nM, for KOR, MOR and DOR, respectively. KOR agonist 1 binds KOR, MOR and DOR, with K_is of 3.9, 1053 and 4196 nM, respectively. KOR agonist 1 exhibits antinociceptive effect in ICR mouse model (ED₅₀ in hot plate test is 0.3 mg/kg, in abdominal constriction test is 0.2 mg/kg) .

HY-108519R

AS1892802 (Standard)	Reference Standards ROCK	Neurological Disease
AS1892802 (Standard) is the analytical standard of AS1892802 (HY-108519). This product is intended for research and analytical applications. AS1892802 is a potent, orally active, and highly selective inhibitor of ROCK. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-108652R

α,β-Methylene-ATP trisodium (Standard)	Reference Standards P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP trisodium (Standard) is the analytical standard of α,β-Methylene-ATP (trisodium) (HY-108652). This product is intended for research and analytical applications. α,β-Methylene-ATP trisodium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .

Cat. No.	Product Name	Target	Research Area